Hostname: page-component-7c8c6479df-24hb2 Total loading time: 0 Render date: 2024-03-27T18:38:54.176Z Has data issue: false hasContentIssue false

Gut microbiota and pregnancy, a matter of inner life

Published online by Cambridge University Press:  15 December 2008

Patrice D. Cani*
Affiliation:
Louvain Drug Research Institute, Metabolism and Nutrition Research Group, Unit of Pharmacokinetics Metabolism Nutrition and Toxicology, Université Catholique de Louvain, Avenue E. Mounier 73/69, B-1200 Brussels, Belgium, fax 32 2 764 73 59, email patrice.cani@uclouvain.be
Rights & Permissions [Opens in a new window]

Extract

More than a century ago, two Nobel Prizes in Physiology and Medicine were awarded to scientists who established the link between microbes and human health.

Type
Invited Commentary
Copyright
Copyright © The Author 2008

More than a century ago, two Nobel Prizes in Physiology and Medicine were awarded to scientists who established the link between microbes and human health. The first one, Robert Koch, linked microbes to infectious diseases, while the second one, Ilya Mechnikov, found that microbes might have beneficial effects on human health. Since then an intricate set of relationships between microbiota and humans has been unravelled. Humans have evolved in – permanent or temporary – intimate association with microbes, contributing to health maintenance or disease.

Look behind your belly button

Over the past 5 years, studies have highlighted some key aspects of the mammalian host–gut microbial relationship. The human gastrointestinal tract contains a diverse collection of micro-organisms totalling about 1014 bacterial cells. It is now recognised that gut microbiota play an even more important role in maintaining human health than previously thought(Reference Jia, Li and Zhao1). What is becoming clear is that these microbes provide us with essential genetic and metabolic attributes, sparing us from the need to evolve on our own. This includes defence against pathogens at the gut level, immunity, digestion and synthesis of several vitamins. Conversely, accumulating evidence indicates that there are also many factors shaping gut microbiota, such as genetics, drugs and environment(Reference Ley, Peterson and Gordon2).

Recently, focus has been placed on therapies that aim to restore a balanced gut microbiota and thereby improving health. However, the mechanisms behind their action on the gut microbiota and their impact on metabolic functions are not fully understood. Today more attention is paid to the role of the balance between gut microbiota and host metabolic functions. The majority of research to date has unveiled a glimpse of the mechanism of action and potential therapeutic role of commensal non-pathogenic microbes (probiotics) on mucosal immunity, inflammatory bowel diseases, allergic diseases and so on(Reference Guarner3Reference Hatakka and Saxelin6). As a consequence, most clinical studies in this area have been designed to explore pathological situations rather than physiological or mildly impaired health situations.

Are the gut microbiota involved in glucose homeostasis during pregnancy?

An article in the current issue of the British Journal of Nutrition assesses the impact of probiotics and dietary counselling on glucose regulation during and after pregnancy(Reference Laitinen, Tuija and Isolauri7). This is the first study describing the effect of probiotic intake on the health of pregnant women. Previous studies in pregnant subjects were conducted in order to study the impact on the gut microbiota on infant instead of the metabolic homeostasis of the mother.

In this new study, Laitinen et al. elegantly demonstrate in a cohort of 256 women that the modulation of gut microbiota composition by probiotics regulates glucose metabolism(Reference Laitinen, Tuija and Isolauri7). The major discovery of the authors is that the blood glucose concentrations were not only lowest in the probiotic group during the first trimester of pregnancy but more importantly over the 12-month postpartum period, while the dietary treatment was interrupted. The maintenance of glucose homeostasis during pregnancy constitutes an important way to reduce the risk of related complications and provides long-term health benefits for the mother and the infant(Reference Crowther, Hiller and Moss8, Reference Ostlund, Hanson and Bjorklund9). This study is in line with recent evidence showing that gut microbiota are involved in the development of obesity, insulin resistance and related disorders such as type 2 diabetes.

What can we learn from the recent literature? Are the gut microbiota involved in the control of glucose homeostasis?

Authors have highlighted that the differences in energy extraction efficiency from food, leading to a higher fat deposition, may be determined by the gut microbiota(Reference Backhed, Ding and Wang10). In humans, the relative proportion of the two major representative phyla of bacteria was different between lean and obese individuals, and a similar result was found in a strain of laboratory mice bred to be genetically obese(Reference Ley, Turnbaugh and Klein11, Reference Turnbaugh, Ley and Mahowald12). Strikingly, the same authors have also demonstrated that germ-free mice were resistant to a high-fat diet-induced obesity and type 2 diabetes(Reference Backhed, Manchester and Semenkovich13), in opposition to the dogma that feeding fat drives the development of obesity and related disorders.

Along this line, our research team argued that the Western diet plays a role in the onset of obesity by reducing or promoting some gut micro-organisms over others in mice models(Reference Delzenne and Cani14, Reference Cani and Delzenne15). Importantly, the data show that fat feeding strongly changes gut microbiota and especially lowers the well-known probiotic strain Bifidobacterium spp. and promotes type 2 diabetes(Reference Cani, Bibiloni and Knauf16, Reference Cani, Amar and Iglesias17). There are several ways to restore the microbial balance, namely by using prebiotics or probiotics. Feeding mice with prebiotic dietary fibres together with the Western diet restored the gut bifidobacteria content, and delayed the onset of obesity, low-grade inflammation, insulin resistance and diabetes(Reference Cani, Neyrinck and Fava18, Reference Cani, Knauf and Iglesias19). Altogether, these findings highlight the role of gut microbiota as an environmental factor involved in the development of obesity and related disorders. However, what is the role of such intervention in physiological conditions such as pregnancy?

Are the gut microbiota the magic bullet?

This is a revolutionary idea that could change our views about the causes of metabolic disorder and glucose homeostasis control: we depend on the bacteria that inhabit our gut. However, most of the data have been obtained in experimental models, and data obtained in human subjects are scarce. In this new study, the authors have not only challenged the role of the gut microbiota in healthy humans but, more importantly, they have provided the first evidence that the gut microbiota can be involved in the control of glucose homeostasis in healthy pregnant women from early pregnancy for up to 1 year postpartum. Again, in this study, Laitinen et al. strongly suggest that the selective modulation of gut microbiota improves serum insulin levels and insulin sensitivity as shown by the homeostasis model assessment (HOMA) and quantitative insulin sensitivity check (QUICKI) indices(Reference Laitinen, Tuija and Isolauri7).

Nevertheless, progress in understanding the mechanisms by which the gut microbiota interact with the host will provide a new basis for putative pharmacological or dietary intervention. Moreover, our current knowledge about the complexity of gut microbiota–host interactions remains scare. Therefore, it is difficult to ascertain the exact mechanisms linking dietary habits, gut microbiota and metabolic disorders.

In conclusion, this new study by Laitinen et al. adds valuable information about the impact of the host and gut microbiota cross-talk during pregnancy. Taken together with the other experimental studies, this study suggests that, rather than not being useful, changing gut microbiota following probiotic ingestion during pregnancy is probably a new area of intervention to prevent or improve glucose homeostasis in such a context. The mechanism and the relevance in pathological conditions (pregnancy diabetes) remain unknown. Therefore, further clinical trials and multidisciplinary research in this field will provide evidence-based data to take into consideration the gut microbiota to treat or prevent metabolic disorders.

P. D. C. is a researcher from the FRS-FNRS (Fonds de la Recherche Scientifique, Belgium). There is no conflict of interest.

References

1Jia, W, Li, H, Zhao, L, et al. (2008) Gut microbiota: a potential new territory for drug targeting. Nat Rev Drug Discov 7, 123129.CrossRefGoogle ScholarPubMed
2Ley, RE, Peterson, DA & Gordon, JI (2006) Ecological and evolutionary forces shaping microbial diversity in the human intestine. Cell 124, 837848.CrossRefGoogle ScholarPubMed
3Guarner, F (2005) Inulin and oligofructose: impact on intestinal diseases and disorders. Br J Nutr 93, Suppl. 1, S61S65.CrossRefGoogle ScholarPubMed
4Guarner, F & Malagelada, JR (2003) Gut flora in health and disease. Lancet 361, 512519.CrossRefGoogle ScholarPubMed
5Lara-Villoslada, F, Olivares, M, Sierra, S, et al. (2007) Beneficial effects of probiotic bacteria isolated from breast milk. Br J Nutr 98, Suppl. 1, S96S100.CrossRefGoogle ScholarPubMed
6Hatakka, K & Saxelin, M (2008) Probiotics in intestinal and non-intestinal infectious diseases – clinical evidence. Curr Pharm Des 14, 13511367.CrossRefGoogle ScholarPubMed
7Laitinen, K, Tuija, P & Isolauri, E (2009) Probiotics and dietary counselling contribute to glucose regulation during and after pregnancy: a randomised controlled trial. Br J Nutr 101, 16791687.CrossRefGoogle ScholarPubMed
8Crowther, CA, Hiller, JE, Moss, JR, et al. (2005) Effect of treatment of gestational diabetes mellitus on pregnancy outcomes. N Engl J Med 352, 24772486.CrossRefGoogle ScholarPubMed
9Ostlund, I, Hanson, U, Bjorklund, A, et al. (2003) Maternal and fetal outcomes if gestational impaired glucose tolerance is not treated. Diabetes Care 26, 21072111.CrossRefGoogle Scholar
10Backhed, F, Ding, H, Wang, T, et al. (2004) The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci U S A 101, 1571815723.CrossRefGoogle ScholarPubMed
11Ley, RE, Turnbaugh, PJ, Klein, S, et al. (2006) Microbial ecology: human gut microbes associated with obesity. Nature 444, 10221023.CrossRefGoogle ScholarPubMed
12Turnbaugh, PJ, Ley, RE, Mahowald, MA, et al. (2006) An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 444, 10271031.CrossRefGoogle ScholarPubMed
13Backhed, F, Manchester, JK, Semenkovich, CF, et al. (2007) Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc Natl Acad Sci U S A 104, 979984.CrossRefGoogle ScholarPubMed
14Delzenne, NM & Cani, PD (2008) Gut microflora is a key player in host energy homeostasis (article in French). Med Sci (Paris) 24, 505510.CrossRefGoogle Scholar
15Cani, PD & Delzenne, NM (2007) Gut microflora as a target for energy and metabolic homeostasis. Curr Opin Clin Nutr Metab Care 10, 729734.CrossRefGoogle ScholarPubMed
16Cani, PD, Bibiloni, R, Knauf, C, et al. (2008) Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 57, 14701481.CrossRefGoogle ScholarPubMed
17Cani, PD, Amar, J, Iglesias, MA, et al. (2007) Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 56, 17611772.CrossRefGoogle ScholarPubMed
18Cani, PD, Neyrinck, AM, Fava, F, et al. (2007) Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia. Diabetologia 50, 23742383.CrossRefGoogle ScholarPubMed
19Cani, PD, Knauf, C, Iglesias, MA, et al. (2006) Improvement of glucose tolerance and hepatic insulin sensitivity by oligofructose requires a functional glucagon-like peptide 1 receptor. Diabetes 55, 14841490.CrossRefGoogle ScholarPubMed